Authors De Backer LA, Vos WG, Salgado R, De Backer JW, Devolder A, Verhulst SL, Claes R, Germonpré PR, De Backer WA Published 28 November 2011 Volume 2011:6 Pages 637—646 DOI https://org/10.2147/COPD.
S21917 Review by Single-blind Peer reviewer comments 2 Department of Radiology, Antwerp University Hospital, Antwerp, Belgium Background: Salbutamol and ipratropium bromide improve lung function in patients with chronic obstructive pulmonary disease (COPD).
However, their bronchodilating effect has not yet been compared in the central and distal airways.
The objective of this study was to assess the effects of salbutamol and ipratropium bromide on the geometry and computational fluid dynamics-based resistance of the central and distal airways.
Methods: Five patients with Global Initiative for Chronic Obstructive Lung Disease Stage III COPD were randomized to a single dose of salbutamol or ipratropium bromide in a crossover manner with a 1-week interval between treatments.
Patients underwent lung function testing and a multislice computed tomography scan of the thorax that was used for functional imaging.
Two hours after dosing, the patients again underwent lung function tests and repeat computed tomography.
supportive but never overbearing; wise people, whom I admire and love dearly. Two of them are still around – they're 20 years old!
They're interested in many things, from music and art to computers and growing vegetables organically. That's one thing I actually wouldn't change about myself though. Actually, if you listen to my records you will probably quickly come to know that. Results: Lung function parameters, including forced expiratory volume in 1 second, vital capacity, overall airway resistance, and specific airway resistance, changed significantly after administration of each product.On functional imaging, the bronchodilating effect was greater in the distal airways, with a corresponding drop in airway resistance, compared with the central airways.Salbutamol and ipratropium bromide were equally effective at first glance when looking at lung function tests, but when viewed in more detail with functional imaging, hyporesponsiveness could be shown for salbutamol in one patient.